Integrin agonists or activating compounds and methods for making and using same

A composition comprising:

• one or more antigens, and
• one or more integrin activating or agonist compounds of the general Formulas:
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6;
• and
• wherein:
• the R1 and R2 groups are independently a —(CH2)-aryl group, or a —(CH2)-heterocyclylaryl group, or the R1 and R2 groups combine to form a fused heterocyclylaryl group including at least one nitrogen-containing aryl group, and
• n independently is an integer having a value between 1 and 6,
• wherein:
• the one or more integrin activating or agonist compounds may be administered before, during, and/or after the administration of the one or more antigens, and
• the one or more integrin activating or agonist compounds activate one or more integrins.